Our technology platform utilizes fluid dynamics ― specifically Taylor-Couette-Poiseuille [TCP] flow ― to generate therapeutics from biologically active gases to restore cellular homeostasis. The goal is to produce drugs like RNS60, which have broad benefits across multiple cell types versus the single receptor-targeted approach that has not proven to be successful in areas like ischemic stroke.

Key biological mechanisms

Our lead candidate, RNS60, activates the Type 1A PI3K-Akt pathway, a master regulator of cell survival. This activation leads to several critical outcomes:

1. Mitochondrial Biogenesis: RNS60 promotes the generation of new, healthy mitochondria, effectively "re-powering" the cell.
2. Enhanced ATP Production: By increasing mitochondrial mass and function, cells gain the energy required for repair and resilience against stress.
3. Enhanced Neuronal Survival: RNS60 activates the Akt-mediated antiapoptotic pathways and increases survival of neurons under various stresses.
4. Immune Modulation: RNS60 modulates the activity of immune cells (like microglia, astroglia and T cells), promoting an anti-inflammatory environment that supports neuroprotection.